A common pathway for an effective anticancer immune response is the recognition of tumor neoantigens and the targeting of cancer cells via T cells. We can use cellular therapies or cancer vaccines to directly augment these two pathways involved in the immune response, focusing on therapeutic development including all types of cancer. Creative BioMart can offer two therapeutic development services including cell therapy and vaccine development, based on MHC-like complexes that can directly identify and isolate antigen-specific T cells or screen and identify MHC-like antigens that can be used for vaccine development.

Introduction

MHC complexes have become an important tool for T-cell analysis, allowing direct identification and isolation of antigen-specific T cells. The development of MHC complexes, through the strategy of combining affinity-purified isolated MHC and antigenic peptides, especially in combination with complexes derived from tumor antigenic peptides, can facilitate the generation of tumor-specific T cell lines in vitro, allowing their precise detection and isolation from multiple specific populations for cancer cell therapy applications.

Fig.1 Tumor antigen presentation pathways (Masafumi N, 2015)

MHC molecules are challenging to identify new antigens for vaccine development due to their high polymorphism and large number of presenting peptides, etc. MHC-like immunopeptidomic studies can identify unique peptides from cancer cells or tumor tissues and can enhance immune responses by selecting and synthesizing cancer vaccine candidates after analyzing and selecting immunopeptidomes, which can provide much support and technical improvements for cancer vaccine design.

Our Services

• MHC Neoepitopes Discovery. The discovery of MHC neo-antigenic epitopes is essential for the design of therapeutic cancer vaccines and immunotherapies, we can offer MHC neoepitope discovery services, including the selection, characterization and monitoring studies of immunogenic neoepitopes for the design of therapeutic cancer vaccines and T-cell therapies, as well as an ever-expanding neoepitope dataset for client program development.
• Cancer Vaccine Development Based on pMHC. Novel antigen immunotherapy with MHC presentation is a promising approach to cancer treatment. Using this approach, we can design cancer vaccines to target tumor-specific mutations not found in normal tissues, enhance the immune response and eradicate tumors. We offer MHC-based cancer vaccine development services to identify tumor-specific peptides that bind to MHC molecules through immunoproteomics approaches.
• Vaccine Development Based on VLPs with MHC Complex. Virus-like particles (VLPs) are a very versatile vaccination tool that can be used as a nanoparticle delivery vehicle for heterologous antigen molecules. Based on this, we can use VLPs as particle scaffolds to demonstrate and deliver specific tumor-associated MHC complex antigens to develop cancer vaccines with enhanced safety and scalability.
• Cell Therapy Discovery Based on TCR-pMHC. Intracellular tumor- or virus-associated antigens can be presented as peptides in cell surface MHCs, which interact with T-cell receptors (TCRs) on antigen-specific T cells to stimulate immune responses. TCR-peptide/MHC-based cell therapy is a promising strategy for the treatment of advanced cancer and viral infections. We offer cell therapy discovery services for cancer treatment.

Our Outstanding Strengths

• MHC immunopeptidomic analysis technology for the discovery of tumor-specific neoantigens.
• High resolution quality and high throughput level of analysis.
• More sensitive, stable and quantitative workflow.
• Multidisciplinary collaboration between biological analysis and computer algorithms.

Creative BioMart offers the most extensive and comprehensive research in the field of MHC analysis for large-scale immunotherapy development. We believe that our advanced technology and broad range of products can provide a rich resource and new insights into personalized immunotherapy for cancer. For more services related to therapy development, you can contact us for detailed resources and explanations.

Reference

• Masafumi N. "Antigen Presentation by MHC-Dressed Cells." Frontiers in Immunology (2015), 5:672.